GlassScriptPhysician profile
Natalie K Mcqueen
NPI 1790179984
$4,358.39
in general payments reported to CMS, 2019-2025
33 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,350 · 2022: $1,040 · 2023: $794 · 2024: $686 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,968.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,395.79 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $374.46 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Lilly USA, LLC | $309.73 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $234.80 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $218.91 | 2021-2024 | Breztri, Airsupra, Farxiga |
| Astellas Pharma US INC | $196.16 | 2021-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $168.16 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.13 | 2021-2023 | Tradjenta, Jardiance, Synjardy |
| Amarin Pharma, INC. | $134.31 | 2021 | |
| Sanofi-Aventis U.S. LLC | $122.59 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $121.19 | 2021-2023 | |
| Esperion Therapeutics, INC. | $117.95 | 2021-2022 | |
| Edwards Lifesciences Corporation | $115.16 | 2025 | |
| Inspire Medical Systems, INC. | $94.00 | 2023-2025 | Inspire |
| Merck Sharp & Dohme LLC | $70.70 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $65.16 | 2021-2025 | General - Erectile Dysfunction |
| Biohaven Pharmaceuticals, INC. | $64.14 | 2021 | |
| Amgen INC. | $63.96 | 2021-2023 | Otezla, Repatha |
| Abbvie INC. | $57.51 | 2022-2024 | |
| Mannkind Corporation | $38.95 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.49 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.76 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $25.36 | 2024 | |
| Glaxosmithkline, LLC. | $19.28 | 2023 | Shingrix, Arexvy |
| Daiichi Sankyo INC. | $17.09 | 2021 | |
| Seqirus USA INC | $14.91 | 2024 | Fluad, Flucelvax |
| Sunovion Pharmaceuticals INC. | $14.58 | 2021 | |
| Eisai INC. | $13.93 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.36 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.58 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.25 | 2021 | |
| Almatica Pharma LLC | $11.97 | 2021 | |
| Pfizer INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Mcqueen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.